The Bioprocessing Research Industry Club (BRIC), a public-private collaboration between two Research Councils and the UK biopharmaceutical community, has awarded £3.5 million to researchers at seven universities. The funding will bring new treatments a step closer by helping to develop faster and more efficient development and manufacturing techniques.
Biopharmaceuticals account for 30 per cent of drugs currently in development, and 10 per cent of the current market. Examples of current biopharmaceutical treatments include the use of therapeutic proteins to manage conditions associated with hormone deficiencies or cancers of breast, colon, prostate or pancreatic tissues. In the future, biopharmaceutical treatments may also be able to help with organ and tissue deficiencies or disease conditions associated with ageing. The projects funded by BRIC aim to improve the bioprocessing techniques and systems that underpin biopharmaceutical development and production.
This is the second round of funding awarded by BRIC - a funding collaboration between the Biotechnology and Biological Sciences Research Council (BBSRC), the Engineering and Physical Sciences Research Council (EPSRC) and the UK biopharmaceutical industry, with support from bioProcessUK. It has awarded funding to eight research teams at seven universities: the Universities of Birmingham, Imperial College London, Manchester, Newcastle, Nottingham, Sheffield and Strathclyde.
These projects build on the first round of BRIC funding which supported nine projects at ten universities with funds in excess of £5 million. The third and final call for BRIC will be announced in the next few weeks.
By combining funding from major public funders and industry, BRIC works to support the rapidly growing biological medicines industry in the UK, with the ultimate aim of accelerating therapy development for patients.
Dr John Birch, Chairman of the BRIC steering group and Chief Scientific Officer at Lonza Biologics, said: "Biological drug development offers tremendous promise for patients. The eight new projects funded by BRIC will make a significant contribution to the research underpinning bioprocessing and will help to provide both faster process development and more efficient manufacturing technology for new biopharmaceuticals."
Dr Doug Yarrow, BBSRC Director of Corporate Science said: "The UK has an outstanding research base in bioprocessing and the latest round of BRIC grants further promotes the UK's world-leading status. It is essential that research capabilities are translated into real benefits for patients. BRIC's funding enables this by strengthening the vital links between groundbreaking research in our universities and industry's needs."
Michelle Kilfoyle | alfa
Researchers identify potentially druggable mutant p53 proteins that promote cancer growth
09.12.2016 | Cold Spring Harbor Laboratory
Plant-based substance boosts eyelash growth
09.12.2016 | Fraunhofer-Institut für Angewandte Polymerforschung IAP
Physicists of the University of Würzburg have made an astonishing discovery in a specific type of topological insulators. The effect is due to the structure of the materials used. The researchers have now published their work in the journal Science.
Topological insulators are currently the hot topic in physics according to the newspaper Neue Zürcher Zeitung. Only a few weeks ago, their importance was...
In recent years, lasers with ultrashort pulses (USP) down to the femtosecond range have become established on an industrial scale. They could advance some applications with the much-lauded “cold ablation” – if that meant they would then achieve more throughput. A new generation of process engineering that will address this issue in particular will be discussed at the “4th UKP Workshop – Ultrafast Laser Technology” in April 2017.
Even back in the 1990s, scientists were comparing materials processing with nanosecond, picosecond and femtosesecond pulses. The result was surprising:...
Have you ever wondered how you see the world? Vision is about photons of light, which are packets of energy, interacting with the atoms or molecules in what...
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
09.12.2016 | Life Sciences
09.12.2016 | Ecology, The Environment and Conservation
09.12.2016 | Health and Medicine